Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
Human iPSC-derived cardiomyocytes combined with the xCELLigence RTCA CardioECR system enables detection of potential cardioactive and proarrhythmic effects of test compounds on the contractility and electrophysiology. This provides a highly relevant in vitro assay to study the cardiac safety profile of compounds during drug development.
Step-by-step instructions to combine hiPSC-derived cardiomyocytes with the xCELLigence RTCA CardioECR system with for impedance and electrophysiology measurements in the following Application Protocol:
The xCELLigence RTCA CardioECR system records cellular impedance (presented as Cell Index (CI)) and electrical field potential (presented as extracellular recording (ECR)) of hiPSC-derived cardiomyocytes in parallel, using proprietary MEA technology. A typical CI trace (top panel) and ECR trace (bottom panel) of a Pluricyte Cardiomyocyte monolayer is shown here.
Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology (presented as extracellular recording (ECR)) and cellular impedance (presented as Cell Index (CI)) of Pluricyte Cardiomyocytes using the xCELLigence RTCA CardioECR system. Pluricyte Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner. Below, an example is shown of the effect of the reference compound, isoproterenol.
Pluricyte Cardiomyocytes show a positive chronotropic and inotropic response to isoproterenol
Isoproterenol activates the β-adrenergic receptor, which results in an increased beat rate (left panel). The impedance signal can be used to assess compound effects on cell contractility. Isoproterenol caused an increase in impedance peak amplitude in Pluricyte Cardiomyocytes (right panel), indicating a positive inotropic effect of isoproterenol.